Advances in epigenetic biomarker research in colorectal cancer

Table 4 MicroRNA biomarkers in the blood and stool of colorectal cancer patients

Markers	Sample	Sensitivity	Specificity	Ref.
Blood
miR-21	186 CRC	76.8%-82.8%	81.1%-90.6%	[77]
	43 A	91.9%	81.1%
	53 controls
miR-601/ miR-760	90 CRC	83.3%	69.1%	[78]
	48 AA	72.1%	62.1%
	58 controls
miR-21	30 CRC	90.0%	90.0%	[79]
	30 controls
miR-29a	258 plasma sample	75.0%	75.0%	[80]
miR-141	102 CRC	77.1%-90.9%	77.1%-89.7%	[81]
miR-92a	120 CRC	84.0%	71.2%	[82]
	37 AA	64.9%	81.4%
	59 controls
miR-29a	120 CRC	69.0%	89.1%	[82]
	37 AA	62.2%	84.70%
	59 controls
miR-221	103 CRC	86.0%	41.0%	[83]
	37 controls
miR-17-3P	90 CRC	64.0%	70.0%	[84]
	50 controls
miR-92a	90 CRC	89.0%	70.0%	[84]
	50 controls
Stool
miR-21	88 CRC	55.7%	73.3%	[85]
	57 polyps	43.9%
	101 controls
miR-92a	88 CRC	71.6%	73.3%	[85]
	57 polyps	56.1%
	101 controls
miR-144*	75 CRC	74.0%	87.0%	[86]
miR 17-92 cluster	197 CRC	69.5%	81.5%	[87]
	119 controls
miR-135	197CRC	46.2%	95.0%	[87]
	119 controls
miR-21	197 CRC	14.7%	91.6%	[87]
	119controls
miR-92a	59 CRC	50.0%	80.0%	[88]
	74 controls
miR-21	59 CRC	50.0%	83.0%	[88]
	74 controls

A: Adenoma; CRC: Colorectal cancer.